Generian Pharmaceuticals
Pittsburgh, US · Founded 2019 · Delaware corporation
Find your way into Generian Pharmaceuticals
532 people in our graph share verified history with the Generian Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.
Javier Solterounlockedknows Hank Safferstein · together at Carnegie Mellon University (overlapped)
×7knows the team · via Carnegie Mellon University
knows the team · via Columbia Business School
×2knows the team · via National Institute of Allergy and Infectious Diseases (NIAID)
knows the team · via The University of Connecticut Health Center
Generian Pharmaceuticals is a preclinical biotechnology company developing orally available small molecule therapeutics for diseases with high unmet need, particularly conditions currently treated by biologics. It targets age-related diseases including metabolic disorders, neurodegeneration, and inflammation.
Founders & leadership
Generian Pharmaceuticals was founded in 2019 by Bill Chen and Yuan Liu.
BC
Bill ChenVice President, Drug Discovery & Co-Founder
YL
Yuan LiuinVice President, Biology & Co-Founder
HS
Hank SaffersteininChief Executive OfficerHank Safferstein is a biotechnology executive and investor with experience in venture capital and senior roles across oncology, neurology, inflammation, and other therapeutic areas, along with expertise in business development, partnerships, and fundraising in the biotech and pharmaceutical sectors.
PL
Po-Shun LeeinChief Medical Officer
AB
Alan BarberChief Financial Officer
BC
Beibei ChenNamed on SEC filing
TF
Toren FinkelChief Scientific Officer & Co-Founder
MK
Matthias KleinzNamed on SEC filing
Board
JC
Jeanne CunicelliBoard director
Reported raises · per SEC filings
Form D private placements$13M disclosed across 1 round · 2019
▶$13MraisedOct 2019 · 1 investors · OtherRule 506(b)
▶$13MraisedOct 2019 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Beibei ChenDirector
- Hank SaffersteinExecutive Officer, Director
- Toren FinkelExecutive Officer, Director
- Jeanne CunicelliDirector
- Matthias KleinzDirector
- Offering amount
- $20M
- Amount sold
- $13M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Ascidian Therapeutics12 shared keywordsAscidian Therapeutics is a biotechnology company developing RNA-based therapeutics, with a clinical focus that includes ophthalmology and inherited retinal diseases.
Lyterian Therapeutics9 shared keywordsLyterian Therapeutics develops pharmaceutical treatments by leveraging protein homeostatic mechanisms to target genetically-validated disease drivers. The company focuses on transformative medicines for patients across multiple disease areas.
Viridian Therapeutics7 shared keywordsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
Regeneron NASDAQ: REGN www.regeneron.com6 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Inipharm6 shared keywordsInipharm is a clinical-stage biopharmaceutical company developing small-molecule inhibitors targeting HSD17B13 to treat severe fibrotic liver diseases, including MASH and other conditions with established genetic validation.
Hunterian Medicine5 shared keywordsHunterian Medicine develops a CRISPR delivery technology using adeno-associated viruses to enable in vivo gene editing for treating genetic diseases. The company targets rare genetic disorders including cystic fibrosis, muscular dystrophy, and ALS, where existing treatments remain unavailable for the vast majority of cases.
Companies competing with Generian Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Generian Pharmaceuticals do?
- Generian Pharmaceuticals is a preclinical biotechnology company developing orally available small molecule therapeutics for diseases with high unmet need, particularly conditions currently treated by biologics. It targets age-related diseases including metabolic disorders, neurodegeneration, and inflammation.
- Who founded Generian Pharmaceuticals?
- Generian Pharmaceuticals was founded by Bill Chen, Yuan Liu in 2019.
- How much funding has Generian Pharmaceuticals raised?
- Generian Pharmaceuticals has disclosed $13M raised across 1 round.
- Where is Generian Pharmaceuticals headquartered?
- Generian Pharmaceuticals is headquartered in Pittsburgh, US.